arrow
T

Thomas Kaley

Memorial Sloan Kettering Cancer Center
H指数:44
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine for newly diagnosed primary CNS lymphoma

伊布替尼联合利妥昔单抗、甲氨蝶呤、长春新碱和丙卡巴肼治疗新诊断的原发性中枢神经系统淋巴瘤

2026-03-010
PRE
Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial

Abemaciclib在具有体细胞NF2或CDK途径改变的脑膜瘤中的应用: 2期联盟A071401试验

2026-01-160
OAAI
Outcomes of inpatient chemoradiotherapy for patients with newly diagnosed glioblastoma and significant functional impairment

新诊断胶质母细胞瘤伴显著功能损害患者住院化放疗的结局

2026-01-010
OA
CTIM-12. DUAL IMMUNE CHECKPOINT BLOCKADE FOR SURGICALLY ACCESSIBLE RECURRENT GLIOBLASTOMA: CLINICAL AND MOLECULAR OUTCOMES

CTIM-12. 双免疫检查点阻断治疗可手术切除的复发性胶质母细胞瘤:临床与分子结局

2025-11-110
OA
CERN 09-02: A PHASE 2 TRIAL OF CARBOPLATIN AND BEVACIZUMAB FOR RECURRENT ADULT EPENDYMOMA

CERN 09-02:一项关于卡铂和贝伐珠单抗治疗复发性成人室管膜瘤的II期临床试验

2025-11-010
OAAI
Glioblastoma distant recurrences preferentially occur along white matter tracts mapped using probabilistic diffusion tractography

胶质母细胞瘤的远处复发倾向于沿着使用概率性扩散纤维追踪技术绘制的白质束发生。

2025-11-010
OAAI
Multicenter basket trial for central nervous system tumors identifies activity of the CDK4/6 inhibitor abemaciclib in recurrent meningioma

多中心篮式试验针对中枢神经系统肿瘤,确定了CDK4/6抑制剂abemaciclib在复发性脑膜瘤中的活性

2025-10-010
PRE
Prospective characterization of germline variants in patients with gliomas and glioneuronal tumors

胶质瘤和神经胶质神经元肿瘤患者胚系变异的前瞻性表征

2025-09-120
OAAI
Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

作者更正: 溶瘤DNX-2401病毒疗法联合pembrolizumab治疗复发性胶质母细胞瘤: 1/2期试验

2025-07-210
OA
Phase Ib study with expansion of ibrutinib, lenalidomide, and rituximab in patients with relapsed/refractory central nervous system lymphoma

Ib期研究:在复发/难治性中枢神经系统淋巴瘤患者中扩大伊布替尼、来那度胺和利妥昔单抗的应用

2025-06-010
PRE
ALLIANCE A071401: GENOMICALLY GUIDED PHASE II TRIAL OF ABEMACICLIB IN PATIENTS WITH GRADE 2/3 MENINGIOMAS HARBORING SOMATIC NF2 OR CDK PATHWAY ALTERATIONS
2024-11-110
PRE
EVALUATION OF PAXALISIB IN GBM AGILE PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA

PAXALISIB在新诊断和复发胶质母细胞瘤的GBM敏捷3期注册平台试验中的评估

2024-11-110
PRE
PROSPECTIVE GERMLINE SEQUENCING OF PATIENTS WITH GLIOMAS, GLIONEURONAL OR NEURONAL TUMORS
2024-11-110
PRE
REAL-WORLD EXPERIENCE WITH CIRCULATING TUMOR DNA IN CEREBROSPINAL FLUID IN PATIENTS WITH CENTRAL NERVOUS SYSTEM TUMORS
2024-11-110
PRE
Real-world experience with circulating tumor DNA in cerebrospinal fluid from patients with central nervous system tumors
2024-09-170
OAAI
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial
2023-05-15113
OAAI
Central Nervous System Cancers, Version 2.2022 Featured Updates to the NCCN Guidelines

中枢神经系统癌症,2.2022版特色更新NCCN指南

2023-01-0176
OA